Cross-Sector entity
Cardinal Health is most often covered alongside McKesson, which appears in 4 of these 4 stories. Across a 36-day span, the pace is roughly 0.8 stories per week. The busiest single day carried 2. The clearest coverage concentration is funding: 2 of 4 stories, with the rest divided among 2 other categories.
4 verified stories tracked
Last mentioned: Aug 2, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Cardinal Health is most often covered alongside McKesson, which appears in 4 of these 4 stories. Across a 36-day span, the pace is roughly 0.8 stories per week. The busiest single day carried 2. The clearest coverage concentration is funding: 2 of 4 stories, with the rest divided among 2 other categories. The tracked stories average 1.5 original sources each. This profile follows 4 Cross-Sector stories mentioning Cardinal Health across the period from June 28, 2026 to August 2, 2026.
Computed from the 4 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Cardinal Health. Shared-story counts are live from our verified record — not editorial picks.
Colorado’s $12M opioid grant round, awarded to 27 organizations, will bolster youth treatment, prison re-entry support, and a rural behavioral health workforce—key gaps in the state’s healthcare delivery system. The highly competitive process drew 287 applications, highlighting the severe need for prevention infrastructure.
Colorado’s distribution of $12 million to 27 groups from opioid settlement funds is the latest reminder of pharma’s enduring financial and reputational liabilities. The grants, part of a broader $700M+ state settlement, fuel prevention programs while underscoring that litigation costs continue to ripple through the industry.
Source: kjct8.com
Amgen and NovoCure represent two extremes in healthcare delivery: a wholesale-dependent drug giant and a patient-centric device innovator. The comparison reveals how direct-to-patient models are reshaping oncology treatment accessibility and reimbursement dynamics.
Amgen brings a massive $36.8B revenue base and a broad chronic disease pipeline, while NovoCure pushes the frontier with electric‑field cancer therapy. This analysis weighs drug development scale against device‑based oncology innovation for biotech investors.
Source: The Motley Fool · Brendan Coffey (us)
